MARKET

FGEN

FGEN

FibroGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.31
+0.26
+1.99%
After Hours: 13.02 -0.29 -2.18% 16:22 07/28 EDT
OPEN
13.20
PREV CLOSE
13.05
HIGH
13.48
LOW
13.12
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
57.21
52 WEEK LOW
12.54
MARKET CAP
1.23B
P/E (TTM)
-6.5660
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 1d ago
Were Hedge Funds Right About FibroGen Inc (FGEN)?
In this article we will check out the progression of hedge fund sentiment towards FibroGen Inc (NASDAQ:FGEN) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company ...
Insider Monkey · 2d ago
Stocks That Hit 52-Week Lows On Monday
    Monday morning saw 115 companies set new 52-week lows.
Benzinga · 2d ago
Don’t Go Bargain Hunting on FibroGen Stock, Says Analyst
Last month, the FDA approved Biogen’s Alezheimer’s disease drug Aducanumab, in a controversial decision that went against the advisory committee’s recommendation. When looking at the case of FibroGen’s (FGEN) roxadustat, the biotech’s therapy for sufferers...
TipRanks · 07/19 23:04
BRIEF-Eluminex Exclusively Licenses Fibrogen’s Biosynthetic Cornea Technology
reuters.com · 07/19 12:42
FibroGen Out-Licenses Recombinant Human Collagen-Based Biosynthetic Cornea
Benzinga · 07/19 12:29
Eluminex Biosciences Exclusively Licenses FibroGen's Biosynthetic Cornea Technology And Recombinant Collagen III Platform; Co. To Pay FibroGen $8M Up Front And Up To $64M In Milestones As Well As $46M In Commercial Milestones
Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based Biosynthetic Cornea Clinical Stage Asset Has Potential for First Approved Biosynthetic Human Cornea Biosynthetic
Benzinga · 07/19 11:06
Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform
Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based Biosynthetic Cornea Clinical Stage Asset Has Potential for First Approved Biosynthetic Human Cornea Biosynthetic Cornea Designed to Address Significant Unmet Nee...
GlobeNewswire · 07/19 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FGEN. Analyze the recent business situations of FibroGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FGEN stock price target is 24.71 with a high estimate of 35.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 305
Institutional Holdings: 79.55M
% Owned: 86.35%
Shares Outstanding: 92.13M
TypeInstitutionsShares
Increased
62
4.95M
New
23
1.04M
Decreased
75
4.50M
Sold Out
35
1.82M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.64%
Pharmaceuticals & Medical Research
+1.92%
Key Executives
Chairman/Director
James Schoeneck
Chief Executive Officer/Director
Enrique Conterno
Chief Financial Officer
Pat Cotroneo
Senior Vice President
Christine Chung
Senior Vice President
Elias Kouchakji
Chief Scientific Officer
John Hunter
Other
Mark Eisner
Other
Thane Wettig
Lead Director/Independent Director
Thomas Kearns
Independent Director
Suzanne Blaug
Independent Director
Aoife Brennan
Independent Director
Benjamin Cravatt
Independent Director
Jeffrey Edwards
Independent Director
Jeffrey Henderson
Independent Director
Maykin Ho
Independent Director
Gerald Lema
Independent Director
Rory Riggs
No Data
About FGEN
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).

Webull offers kinds of FibroGen Inc stock information, including NASDAQ:FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.